(+)-Syringaresinol, a lignan, is a NFAT transcription factor inhibitor, with an IC 50 of 329.4 μM. (+)-Syringaresinol also can be used for the research of lymphocytic leukemiaIn Vitro(+)-Syringaresinol inhibits the growth of P-388 cells, with an ED
(+)-Syringaresinol, a lignan, is a NFAT transcription factor inhibitor, with an IC 50 of 329.4 μM. (+)-Syringaresinol also can be used for the research of lymphocytic leukemiaIn Vitro(+)-Syringaresinol inhibits the growth of P-388 cells, with an ED
(+)-Syringaresinol, a lignan, is a NFAT transcription factor inhibitor, with an IC 50 of 329.4 μM. (+)-Syringaresinol also can be used for the research of lymphocytic leukemiaIn Vitro(+)-Syringaresinol inhibits the growth of P-388 cells, with an ED
(+)-Syringaresinol, a lignan, is a NFAT transcription factor inhibitor, with an IC 50 of 329.4 μM. (+)-Syringaresinol also can be used for the research of lymphocytic leukemiaIn Vitro(+)-Syringaresinol inhibits the growth of P-388 cells, with an ED
(D)-PPA 1 TFA is a hydrolysisresistant d-peptide antagonist. (D)-PPA 1 TFA serves as a potent PD-1/PD-L1 inhibitor. (D)-PPA 1 TFA binds to PD-1 with the affinity 0f 0.51 μM with in vitro and in vivo efficacy.Appearance:SolidIn Vitro:(D)-PPA 1 TFA
(D)-PPA 1 TFA is a hydrolysisresistant d-peptide antagonist. (D)-PPA 1 TFA serves as a potent PD-1/PD-L1 inhibitor. (D)-PPA 1 TFA binds to PD-1 with the affinity 0f 0.51 μM with in vitro and in vivo efficacy.Appearance:SolidIn Vitro:(D)-PPA 1 TFA
(D)-PPA 1 TFA is a hydrolysisresistant d-peptide antagonist. (D)-PPA 1 TFA serves as a potent PD-1/PD-L1 inhibitor. (D)-PPA 1 TFA binds to PD-1 with the affinity 0f 0.51 μM with in vitro and in vivo efficacy.Appearance:SolidIn Vitro:(D)-PPA 1 TFA
(D)-PPA 1 TFA is a hydrolysisresistant d-peptide antagonist. (D)-PPA 1 TFA serves as a potent PD-1/PD-L1 inhibitor. (D)-PPA 1 TFA binds to PD-1 with the affinity 0f 0.51 μM with in vitro and in vivo efficacy.Appearance:SolidIn Vitro:(D)-PPA 1 TFA
(D)-PPA 1 TFA is a hydrolysisresistant d-peptide antagonist. (D)-PPA 1 TFA serves as a potent PD-1/PD-L1 inhibitor. (D)-PPA 1 TFA binds to PD-1 with the affinity 0f 0.51 μM with in vitro and in vivo efficacy.Appearance:SolidIn Vitro:(D)-PPA 1 TFA
(D)-PPA 1 TFA is a hydrolysisresistant d-peptide antagonist. (D)-PPA 1 TFA serves as a potent PD-1/PD-L1 inhibitor. (D)-PPA 1 TFA binds to PD-1 with the affinity 0f 0.51 μM with in vitro and in vivo efficacy.Appearance:SolidIn Vitro:(D)-PPA 1 TFA
(E/Z)-Eltrombopag- 13 C 4 is a mixture complex of E-Eltrombopag and Z-Eltrombopag, with 13 C labeled. Z-Eltrombopag is an orally active thrombopoietin receptor nonpeptide agonist. Eltrombopag owns thrombopoietic activity, and has been used to
(E/Z)-Eltrombopag- 13 C 4 is a mixture complex of E-Eltrombopag and Z-Eltrombopag, with 13 C labeled. Z-Eltrombopag is an orally active thrombopoietin receptor nonpeptide agonist. Eltrombopag owns thrombopoietic activity, and has been used to
(Rac)-ZLc-002, an inhibitor of nNOS interaction with nitric oxide synthase 1 adaptor protein (NOS1AP) , suppresses inflammatory nociception and chemotherapy-induced neuropathic pain and synergizes with Paclitaxel ( HY-B0015 ) to reduce tumor cell
(Rac)-ZLc-002, an inhibitor of nNOS interaction with nitric oxide synthase 1 adaptor protein (NOS1AP) , suppresses inflammatory nociception and chemotherapy-induced neuropathic pain and synergizes with Paclitaxel ( HY-B0015 ) to reduce tumor cell
(Rac)-ZLc-002, an inhibitor of nNOS interaction with nitric oxide synthase 1 adaptor protein (NOS1AP) , suppresses inflammatory nociception and chemotherapy-induced neuropathic pain and synergizes with Paclitaxel ( HY-B0015 ) to reduce tumor cell
(Rac)-ZLc-002, an inhibitor of nNOS interaction with nitric oxide synthase 1 adaptor protein (NOS1AP) , suppresses inflammatory nociception and chemotherapy-induced neuropathic pain and synergizes with Paclitaxel ( HY-B0015 ) to reduce tumor cell
(Rac)-ZLc-002, an inhibitor of nNOS interaction with nitric oxide synthase 1 adaptor protein (NOS1AP) , suppresses inflammatory nociception and chemotherapy-induced neuropathic pain and synergizes with Paclitaxel ( HY-B0015 ) to reduce tumor cell
(Rac)-ZLc-002, an inhibitor of nNOS interaction with nitric oxide synthase 1 adaptor protein (NOS1AP) , suppresses inflammatory nociception and chemotherapy-induced neuropathic pain and synergizes with Paclitaxel ( HY-B0015 ) to reduce tumor cell
(Rac)-ZLc-002, an inhibitor of nNOS interaction with nitric oxide synthase 1 adaptor protein (NOS1AP) , suppresses inflammatory nociception and chemotherapy-induced neuropathic pain and synergizes with Paclitaxel ( HY-B0015 ) to reduce tumor cell
(Rac)-ZLc-002, an inhibitor of nNOS interaction with nitric oxide synthase 1 adaptor protein (NOS1AP) , suppresses inflammatory nociception and chemotherapy-induced neuropathic pain and synergizes with Paclitaxel ( HY-B0015 ) to reduce tumor cell
2-Iminobiotin hydrobromide (Guanidinobiotin hydrobromide) is a biotin (vitamin H or B7) analog. 2-Iminobiotin hydrobromide is a reversible nitric oxide synthases inhibitor with K i s of 21.8 and 37.5 μM for murine iNOS and rat n-cNOS , respectively
2-Iminobiotin hydrobromide (Guanidinobiotin hydrobromide) is a biotin (vitamin H or B7) analog. 2-Iminobiotin hydrobromide is a reversible nitric oxide synthases inhibitor with K i s of 21.8 and 37.5 μM for murine iNOS and rat n-cNOS , respectively
2-Iminobiotin hydrobromide (Guanidinobiotin hydrobromide) is a biotin (vitamin H or B7) analog. 2-Iminobiotin hydrobromide is a reversible nitric oxide synthases inhibitor with K i s of 21.8 and 37.5 μM for murine iNOS and rat n-cNOS , respectively
2-Iminobiotin hydrobromide (Guanidinobiotin hydrobromide) is a biotin (vitamin H or B7) analog. 2-Iminobiotin hydrobromide is a reversible nitric oxide synthases inhibitor with K i s of 21.8 and 37.5 μM for murine iNOS and rat n-cNOS , respectively